Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10910826 | Lung Cancer | 2015 | 44 Pages |
Abstract
The 181946C>T polymorphisms in the EGFR gene seems to be a potential predictor of higher DCR, longer PFS and OS in advanced NSCLC patients treated with erlotinib, especially in EGFR mutation-positive patients. Thus, this SNP may be a new potential tool for selection of patients for treatment. Prospective randomized studies are wanted to confirm our data.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anne Winther-Larsen, Peter Henrik Nissen, Kristine Raaby Jakobsen, Christina Demuth, Boe Sandahl Sorensen, Peter Meldgaard,